COMMUNIQUÉS West-GlobeNewswire

Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive Officer
23/07/2025
Proven drug development leader to drive company’s pipeline of highly CNS-penetrant and precision-designed peripherally restricted small molecules toward clinical milestones SOUTH SAN FRANCISCO, Calif., July 23, 2025 ( [...]
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
23/07/2025
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed [...]
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
23/07/2025
Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
23/07/2025
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Yarema, Ph.D. as Chief [...]
Qu Biologics Completes Enrolment of a Unique Study Testing a Novel Immunomodulator to Restore Immune Function in the Elderly
23/07/2025
VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation platform designed [...]
Philips advances minimally invasive therapy procedures in prostate cancer care with FDA 510(k) clearance for image-guided navigation technology
23/07/2025
July 23, 2025 Supporting prostate cancer diagnosis with more precise guidance for clinicians, offering better patient care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health [...]
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock
23/07/2025
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock Published in Intensive Care Medicine, Inotrem’s results highlight the pivotal role of the soluble TREM-1 [...]
PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio
23/07/2025
New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing MENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high- [...]
AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers to Protect Market Share Across Brand, Biosimilar and Generic Launches
23/07/2025
BERWYN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces service and infrastructure enhancements [...]
SAFE - Signature d’un avenant n°5 au contrat de financement obligataire en vigueur afin de poursuivre le retournement stratégique de Safe
23/07/2025
Avertissement : La société SAFE SA (la « Société ») a mis en place un financement sous forme d’obligations convertibles en actions nouvelles ou existantes (OCEANE) avec Global Corporate Finance Opportunities 20 (« GCFO [...]
European Commission approves IMBRUVICA® (ibrutinib) as the first targeted therapy for patients with previously untreated mantle cell lymphoma who would be eligible for autologous stem cell transplant
23/07/2025
Ibrutinib is the first approved Bruton’s tyrosine kinase (BTK) inhibitor to demonstrate statistically meaningful outcomes versus autologous stem cell transplant (ASCT) for the frontline treatment of transplant eligible [...]
European Commission approves DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma
23/07/2025
Landmark approval is based on results from the Phase 3 AQUILA study, showing fixed-duration treatment with daratumumab significantly reduced the risk of progression to active multiple myeloma or death by 51 percent [...]
4TEEN4 Doses First Patient in Phase 1b/2a Trial of Procizumab, a Monoclonal Antibody Targeting the Biological Driver of Shock
23/07/2025
The trial will evaluate safety, dosing, and efficacy in patients with cardiogenic shock Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase [...]
dacadoo Forges Collaboration with Microsoft to Transform Digital Health Engagement in the Era of AI
23/07/2025
Zurich, CH, July 23, 2025 (GLOBE NEWSWIRE) -- dacadoo, a global leader in digital health engagement & health scoring announced today a collaboration with Microsoft to deliver next-generation digital health [...]
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
23/07/2025
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented [...]
Conavi Medical Applauds New American Journal of Cardiology Study Highlighting Importance of Intracoronary Imaging During PCI
23/07/2025
TORONTO, July 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intracoronary imaging technologies, is pleased to highlight the recent publication in The American Journal [...]
Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025
23/07/2025
WEST LAFAYETTE, Ind., July 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
23/07/2025
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including [...]
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
23/07/2025
FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma [...]

Pages